In the North American pharmaceutical industry, there were 264 M&A deals announced in Q2 2023, worth a total value of $38bn, according to GlobalData’s Deals Database. The $10.8bn acquisition of prometheus biosciences by merck was the industry’s largest disclosed deal. A thorough analysis of the disruptive themes, the M&A activity and most notable deals are included in GlobalData’s Pharma Industry Mergers and Acquisitions Deals by Top Themes report. Buy the report here.
In value terms, M&A activity in North America decreased by 41% in Q2 2023 compared with the previous quarter’s total of $64.5bn and rose by 48% as compared to Q2 2022. Related deal volume increased by 27% in Q2 2023 versus the previous quarter and was 156% higher than in Q2 2022.
The top-ranked financial advisors supporting these M&A deals in North America in Q2 2023 were Centerview Partners; Stifel Financial; Goldman Sachs Group with 12, 6, 5 deals respectively.
The top-ranked legal advisors supporting these M&A deals in North America Q2 2023 were Kirkland & Ellis; Cooley; Gibson, Dunn & Crutcher with 13, 12, 11 deals respectively.
For further understanding of GlobalData's Pharma Industry Mergers and Acquisitions Deals by Top Themes, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
Smarter leaders trust GlobalData
Premium Insights Pharma Industry Mergers and Acquisitions Deals by Top Themes in 2022 - Thematic Intelligence
Premium Insights
The gold standard of business intelligence.
